Company intelligence / Profile preview

Mabtech

Ownership: Private
Development stage: Commercial

Overview

Mabtech's immunoassay solutions (ELISpot, FluoroSpot, ELISA) are widely recognized and validated, with over 4500 scientific citations, supporting immune response studies in a variety of research areas. The company does not develop therapeutic drugs or clinical candidates but provides tools essential for both preclinical and clinical immune monitoring[1][2][3].

Therapeutic areas: ImmunologyInfectious DiseasesOtherOncologyCardiovascular
Modalities: Monoclonal antibodyAntibodyProteinRecombinant protein
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Mabtech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mabtech.

Explore the full profile